Free Trial
→ Tomorrow morning's stock alert (From The Early Bird) (Ad)tc pixel Free OBD Stock Alerts

Oxford BioDynamics (OBD) Competitors

Oxford BioDynamics logo
GBX 0.19 0.00 (-0.53%)
As of 12:01 PM Eastern
Compare

OBD vs. COS, C4XD, DDDD, IMM, and AREC

Should you buy Oxford BioDynamics stock or one of its competitors? MarketBeat compares Oxford BioDynamics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oxford BioDynamics include Collagen Solutions plc (COS.L) (COS), C4X Discovery (C4XD), 4D pharma (DDDD), ImmuPharma (IMM), and Arecor Therapeutics (AREC). These companies are all part of the "biotechnology" industry.

How does Oxford BioDynamics compare to Collagen Solutions plc (COS.L)?

Collagen Solutions plc (COS.L) (LON:COS) and Oxford BioDynamics (LON:OBD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Collagen Solutions plc (COS.L) has higher revenue and earnings than Oxford BioDynamics. Oxford BioDynamics is trading at a lower price-to-earnings ratio than Collagen Solutions plc (COS.L), indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Collagen Solutions plc (COS.L)£4.01M0.00N/A-£0.80N/A
Oxford BioDynamics£1.10M7.29-£103.52M-£0.80N/A

In the previous week, Collagen Solutions plc (COS.L)'s average media sentiment score of 0.00 equaled Oxford BioDynamics'average media sentiment score.

Company Overall Sentiment
Collagen Solutions plc (COS.L) Neutral
Oxford BioDynamics Neutral

25.4% of Oxford BioDynamics shares are held by institutional investors. 15.6% of Oxford BioDynamics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Collagen Solutions plc (COS.L) has a net margin of 0.00% compared to Oxford BioDynamics' net margin of -1,018.54%. Collagen Solutions plc (COS.L)'s return on equity of 0.00% beat Oxford BioDynamics' return on equity.

Company Net Margins Return on Equity Return on Assets
Collagen Solutions plc (COS.L)N/A N/A N/A
Oxford BioDynamics -1,018.54%-316.67%-56.23%

Summary

Collagen Solutions plc (COS.L) beats Oxford BioDynamics on 4 of the 7 factors compared between the two stocks.

How does Oxford BioDynamics compare to C4X Discovery?

Oxford BioDynamics (LON:OBD) and C4X Discovery (LON:C4XD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

In the previous week, Oxford BioDynamics' average media sentiment score of 0.00 equaled C4X Discovery'saverage media sentiment score.

Company Overall Sentiment
Oxford BioDynamics Neutral
C4X Discovery Neutral

Oxford BioDynamics has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market. Comparatively, C4X Discovery has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market.

C4X Discovery has higher revenue and earnings than Oxford BioDynamics. Oxford BioDynamics is trading at a lower price-to-earnings ratio than C4X Discovery, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oxford BioDynamics£1.10M7.29-£103.52M-£0.80N/A
C4X Discovery£24.68M0.00£10.57M£0.04N/A

C4X Discovery has a net margin of 42.81% compared to Oxford BioDynamics' net margin of -1,018.54%. C4X Discovery's return on equity of 55.38% beat Oxford BioDynamics' return on equity.

Company Net Margins Return on Equity Return on Assets
Oxford BioDynamics-1,018.54% -316.67% -56.23%
C4X Discovery 42.81%55.38%28.04%

25.4% of Oxford BioDynamics shares are held by institutional investors. Comparatively, 52.1% of C4X Discovery shares are held by institutional investors. 15.6% of Oxford BioDynamics shares are held by company insiders. Comparatively, 27.1% of C4X Discovery shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

C4X Discovery beats Oxford BioDynamics on 9 of the 10 factors compared between the two stocks.

How does Oxford BioDynamics compare to 4D pharma?

Oxford BioDynamics (LON:OBD) and 4D pharma (LON:DDDD) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

4D pharma has a net margin of 0.00% compared to Oxford BioDynamics' net margin of -1,018.54%. 4D pharma's return on equity of -89.48% beat Oxford BioDynamics' return on equity.

Company Net Margins Return on Equity Return on Assets
Oxford BioDynamics-1,018.54% -316.67% -56.23%
4D pharma N/A -89.48%-42.64%

25.4% of Oxford BioDynamics shares are owned by institutional investors. Comparatively, 26.8% of 4D pharma shares are owned by institutional investors. 15.6% of Oxford BioDynamics shares are owned by insiders. Comparatively, 12.2% of 4D pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

4D pharma has lower revenue, but higher earnings than Oxford BioDynamics. Oxford BioDynamics is trading at a lower price-to-earnings ratio than 4D pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oxford BioDynamics£1.10M7.29-£103.52M-£0.80N/A
4D pharma£718K0.00-£31.94M-£15.40N/A

In the previous week, Oxford BioDynamics' average media sentiment score of 0.00 equaled 4D pharma'saverage media sentiment score.

Company Overall Sentiment
Oxford BioDynamics Neutral
4D pharma Neutral

Oxford BioDynamics has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market. Comparatively, 4D pharma has a beta of 2.63, suggesting that its share price is 163% more volatile than the broader market.

Summary

4D pharma beats Oxford BioDynamics on 6 of the 10 factors compared between the two stocks.

How does Oxford BioDynamics compare to ImmuPharma?

Oxford BioDynamics (LON:OBD) and ImmuPharma (LON:IMM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, dividends and analyst recommendations.

ImmuPharma has lower revenue, but higher earnings than Oxford BioDynamics. ImmuPharma is trading at a lower price-to-earnings ratio than Oxford BioDynamics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oxford BioDynamics£1.10M7.29-£103.52M-£0.80N/A
ImmuPharmaN/AN/A-£2.51M-£0.37N/A

In the previous week, ImmuPharma had 1 more articles in the media than Oxford BioDynamics. MarketBeat recorded 1 mentions for ImmuPharma and 0 mentions for Oxford BioDynamics. Oxford BioDynamics' average media sentiment score of 0.00 equaled ImmuPharma'saverage media sentiment score.

Company Overall Sentiment
Oxford BioDynamics Neutral
ImmuPharma Neutral

25.4% of Oxford BioDynamics shares are owned by institutional investors. Comparatively, 6.1% of ImmuPharma shares are owned by institutional investors. 15.6% of Oxford BioDynamics shares are owned by insiders. Comparatively, 6.5% of ImmuPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

ImmuPharma has a net margin of 3,519.56% compared to Oxford BioDynamics' net margin of -1,018.54%. Oxford BioDynamics' return on equity of -316.67% beat ImmuPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Oxford BioDynamics-1,018.54% -316.67% -56.23%
ImmuPharma 3,519.56%-1,397.44%-43.00%

Oxford BioDynamics has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market. Comparatively, ImmuPharma has a beta of 2.975, suggesting that its share price is 198% more volatile than the broader market.

Summary

ImmuPharma beats Oxford BioDynamics on 6 of the 11 factors compared between the two stocks.

How does Oxford BioDynamics compare to Arecor Therapeutics?

Arecor Therapeutics (LON:AREC) and Oxford BioDynamics (LON:OBD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Arecor Therapeutics has a beta of -0.18, indicating that its stock price is 118% less volatile than the broader market. Comparatively, Oxford BioDynamics has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market.

In the previous week, Arecor Therapeutics' average media sentiment score of 0.00 equaled Oxford BioDynamics'average media sentiment score.

Company Overall Sentiment
Arecor Therapeutics Neutral
Oxford BioDynamics Neutral

Arecor Therapeutics has a net margin of 38.74% compared to Oxford BioDynamics' net margin of -1,018.54%. Arecor Therapeutics' return on equity of 14.26% beat Oxford BioDynamics' return on equity.

Company Net Margins Return on Equity Return on Assets
Arecor Therapeutics38.74% 14.26% -37.31%
Oxford BioDynamics -1,018.54%-316.67%-56.23%

6.0% of Arecor Therapeutics shares are held by institutional investors. Comparatively, 25.4% of Oxford BioDynamics shares are held by institutional investors. 4.8% of Arecor Therapeutics shares are held by company insiders. Comparatively, 15.6% of Oxford BioDynamics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Arecor Therapeutics has higher revenue and earnings than Oxford BioDynamics. Oxford BioDynamics is trading at a lower price-to-earnings ratio than Arecor Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arecor Therapeutics£1.71M14.98-£10.68M£2.0034.00
Oxford BioDynamics£1.10M7.29-£103.52M-£0.80N/A

Summary

Arecor Therapeutics beats Oxford BioDynamics on 8 of the 11 factors compared between the two stocks.

Get Oxford BioDynamics News Delivered to You Automatically

Sign up to receive the latest news and ratings for OBD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OBD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OBD vs. The Competition

Export
MetricOxford BioDynamicsBiotechnology IndustryMedical SectorLON Exchange
Market Cap£7.98M£436.33M£6.48B£2.71B
Dividend YieldN/A3.86%2.67%6.16%
P/E Ratio-0.233.1824.57366.28
Price / Sales7.296,656.32531.6386,890.05
Price / Cash3.9813.1326.9927.85
Price / Book0.2387.1010.537.71
Net Income-£103.52M-£96.07M£3.56B£5.89B
7 Day Performance10.06%-2.21%-0.88%-0.75%
1 Month Performance3.33%0.13%1.45%1.84%
1 Year Performance-51.94%53.46%21.50%71.71%

Oxford BioDynamics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OBD
Oxford BioDynamics
N/AGBX 0.19
-0.5%		N/A-51.4%£7.98M£1.10MN/A45
COS
Collagen Solutions plc (COS.L)
N/AN/AN/AN/A£30.99M£4.01MN/A3,350
C4XD
C4X Discovery
N/AN/AN/AN/A£30.27M£24.68M300.0049
DDDD
4D pharma
N/AN/AN/AN/A£30.05M£718KN/A106
IMM
ImmuPharma
N/AGBX 4.33
-2.3%		N/A+70.5%£27.02MN/AN/A13

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:OBD) was last updated on 6/9/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel